SSRIs Combined RTMS To Treat OCD Curative Effect And Transshipment Gene Polymorphisms

Objective:Comparing SSRIs drug therapy and drug combination rTMS treatment effectiveness of patients with obsessive-compulsive disorder,after exploring 5-HT SLC6A4 transporter gene and glutamate transporter gene SLC1A1 single nucleotide polymorphisms associated with SSRIs and rTMS treatment of obsessive-compulsive disorder,the connection between the curative effect of individualized,provides the theory basis for accurate treatment of obsessive-compulsive disorder,joint assessment SSRIs and rTMS therapeutic treatment of obsessive-compulsive disorder and genetics possible mechanism.Method:This research adopts the study,the research methods in the control group,the group of patients with ocd group 16 cases and the control group,30 cases respectively the general demographic data collection,inventory assessment and peripheral blood collection.Then DNA extraction was performed and genotyping was performed using the PCR-RFLP genotyping method.In the study group,patients with obsessive-compulsive disorder were treated with SSRIs combined with rTMS,and the control group only treated with SSRIs,then evaluated the therapeutic effect and obtained effective treatment data.comprehensive the above information,using SPSS17.0 software package for general data statistical analysis,using the SHEsis software the genotyping data are Hardy Weinberg equilibrium test and allele frequency statistical analysis.Result: a.The treatment group and the control group had no statistical differences in gender,age,education years,occupation,family genetic history,etc.(p >0.05).b.Treatment group and control group patients after 2 weeks Y-BOCS score significantly lower(p < 0.05),the treatment group patients after treatment of 4 weeks Y-BOCS score still continue to reduce,and the control group patients after treatmentof 4 weeks Y-BOCS score no statistical differences compared with before treatment.c.Compared with the control group,the two sites of SLC1A1 gene,rs301430,rs12682807,and SLC6A4 gene,5-httlpr,rs25531,had good correlation with the expected value.d.There was no statistical difference in the frequency distribution of alleles,genotypes,and carriers of the two alleles on the SLC6A4 genotype two sites 5-httlpr and rs25531(p >0.05).e.There were no statistically significant differences in the frequency distribution of alleles,genotypes,and carriers of the two alleles in the SLC6A4 genotype two sites5-httlpr and rs25531,but there were statistical differences in allele L and S carriers.(p < 0.05).f.There was no statistical difference in the frequency distribution between the genotype and the two allele carriers in the rs301430 and rs12682807 of the SLC1A1 genotype of the drug effective group and the invalid group,but in rs301430 allele C and rs12682807 allele A statistically significant(p < 0.05).g.SSRIs joint rTMS treatment effective and ineffective group participants in SLC6A4 locus 5-httlpr and rs25531 allele and genotype,two alleles of carrier frequency distribution statistical differences and the difference is significant(p <0.05).Conclusion: a.SSRIs combined with rTMS to treat obsessive-compulsive disorder with high efficacy,high safety,and no increase in side effects,especially in patients with anxiety and sleep disorders.b.SLC6A4 single nucleotide polymorphic 5-httlpr allele was better than other allele carriers after 12 weeks of treatment with SSRIs,the allele C of SLC1A1 single nucleotide polymorphic RS301430 is not sensitive to SSRIs.c.SLC6A4 single nucleotide polymorphic 5-httlpr allele S has a better therapeutic effect on SSRIs combined with rTMS,patients with SS and SA/SA were more sensitive to joint treatment,the combination therapy with allele LA and LG was not effective.